STZ - Constellation Brands, Inc.

NYSE - NYSE Delayed Price. Currency in USD
-2.01 (-0.97%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close206.80
Bid204.40 x 800
Ask204.85 x 900
Day's Range204.77 - 207.67
52 Week Range150.37 - 234.26
Avg. Volume1,928,426
Market Cap38.923B
Beta (3Y Monthly)0.83
PE Ratio (TTM)11.66
EPS (TTM)17.57
Earnings DateJun 27, 2019 - Jul 1, 2019
Forward Dividend & Yield3.00 (1.69%)
Ex-Dividend Date2019-05-09
1y Target Est223.09
Trade prices are not sourced from all markets
  • Fortune 500 company takes majority stake in Nashville distillery
    American City Business Journals2 days ago

    Fortune 500 company takes majority stake in Nashville distillery

    Nelson’s Green Brier Distillery has a deep-pocketed new majority owner. Constellation Brands Inc. (NYSE: STZ) took a majority stake in the Nashville-based distillery earlier this month, according to a news release.

  • Why Canopy Growth’s Deals May Not Translate Into Gains for CGC Stock
    InvestorPlace2 days ago

    Why Canopy Growth’s Deals May Not Translate Into Gains for CGC Stock

    Canopy Growth (NYSE:CGC) moved higher after announcing a deal with its investment arm, Canopy Rivers (OTCMKTS:CNPOF). This offers some relief to CGC stock, which had returned to levels not seen since before they announced their buyout intentions on Acreage Holdings (OTCMKTS:ACRGF).Source: Shutterstock Unfortunately, Canopy Growth stock seems to need more. CGC has again sold off after briefly crossing the $50 per share mark in late April. While the deals with Canopy Rivers and Acreage boost the long-term prospects of Canopy Growth Corporation, they also show the difficulty of breaking CGC stock out of its current trading range. Canopy Growth Continues to Improve Market PositioningCanopy Rivers announced that the portfolio company it owns, PharmHouse Inc., will commit more of its production to Canopy Growth. CGC will now buy an additional 20% of PharmHouse's output for the next three years. PharmHouse had previously committed 10% of its flowering space to Canopy Growth.InvestorPlace - Stock Market News, Stock Advice & Trading TipsStill, despite what the PharmHouse deal means to Canopy Growth, much of the focus has settled on mergers and acquisitions (M&A). The latest M&A deal for Canopy involves a buyout of New York-based Acreage Holdings. However, in reality, one could better describe this "agreement" as an option. The deal will not close until recreational weed becomes legal across the U.S. * 7 Stocks to Buy that Lost 10% Last Week I agree with my InvestorPlace colleague Tom Taulli that the alliance with Constellation Brands (NYSE:STZ) alliance holds Canopy Growth in good stead. I also believe the company has positioned itself for a leadership position in the U.S. in both hemp and cannabidiol (CBD). This benefits the firm without regard to what happens with the Acreage deal. I also see Canopy Growth remaining the market leader in North America when U.S.-based companies can operate with full legal status. Investors Should Separate Canopy Growth, CGC stockStill, what helps Canopy Growth may or may not boost Canopy Growth stock. The current hype regarding marijuana stocks renders the price-to-sales (P/S) ratio of around 135X meaningless. However, it also leaves investors without a valuation-based metric with which to evaluate CGC stock.Hence, this leaves investors with the charts as a guide. For all of the hype, Canopy Growth stock has twice pulled back after spiking above $55 per share in intraday trading. In recent weeks, even the Acreage deal could not keep CGC stock above $50 per share. Moreover, since Jan. 15, it has rarely moved below $40 per share or above $50 per share. CGC Stock Has Become Range-BoundDespite its elevated multiple, I do not think it will break through the lower end of the range unless a recession occurs, or the U.S. suddenly makes cannabis legal.For now, traders have focused on when and how CGC stock will break through on the high end of the range. The elevated P/S ratio will struggle to go even higher without further stimulus. However, seeing the rally fizzle after the stock moved past $50 per share could make one wonder whether stimulus truly helps. Moreover, seeing marijuana stocks (including CGC) tank after weed became officially legal in Canada remains fresh on investor's minds. It also shows the strange and powerful phenomenon of illegality driving cannabis equities.Like most, I believe CGC stock will trade at higher levels years from now. However, until we see the stock stay above $55 per share, I do not think that the higher stock price will come in the near term. Final Thoughts on CGC StockCGC stock trades near the high end of its range, and I expect CGC will stay in the range. The PharmHouse deal serves as yet another confirmation that the growth story remains intact for Canopy Growth. However, it will likely not have a material effect on Canopy Growth stock. * 10 Stocks to Sell Before They Tank Your Portfolio Moreover, before the company announced this deal, CGC had fallen back to levels it saw before they announced the Acreage Holdings deal. Simply put, CGC stock has become range-bound.The prospects of the cannabis industry should keep Canopy Growth stock at an elevated multiple in the near term. However, even a major coup such as the Acreage deal has failed to put CGC stock back on a growth trajectory.The Acreage and the PharmHouse deals show that Canopy Growth has both the strategic vision and the product needed to lead the marijuana industry. Unfortunately, translating this insight into near-term growth for Canopy Growth stock will prove more elusive.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Buy that Lost 10% Last Week * Top 7 Dow Jones Stocks of 2019 -- So Far * 5 Service Stocks That Can Win the Trade War -- According to Goldman Sachs Compare Brokers The post Why Canopy Growth's Deals May Not Translate Into Gains for CGC Stock appeared first on InvestorPlace.

  • InvestorPlace2 days ago

    Why Canopy Growth Stock Isn’t Worth Buying Yet

    There may very well be at least three reasons to not sell Canopy Growth (NYSE:CGC) stock. But the price chart is warning investors that they shouldn't buy CGC stock now. Let me explain.I enjoy reading InvestorPlace contributor Luke Lango's take on the markets. His analysis personally turned me on to both Shopify (NYSE:SHOP) and Twilio (NYSE:TWLO) long ago when many other traders and financial pundits were warning of their downside risks well before their subsequent, massive, triple-digit-percentage gains. KAAACCHHINGG! * 6 Chinese Stocks That Could Pop On a Trade Deal But getting back to Canopy Growth stock, this week Luke wrote that investors shouldn't sell Canopy Growth. The first reason he cited was trade-war headwinds being overblown and not really an issue for CGC. I totally agree with that. Still, that doesn't make Canopy Growth stock worth buying.InvestorPlace - Stock Market News, Stock Advice & Trading TipsLuke also wrote that the slowdown in Canada's cannabis market isn't actually terribly alarming and discussed the tailwind of the still-untapped U.S. market. Those points are good reasons to not sell CGC stock, but they fail to make Canopy Growth stock worth buying at the moment.Now don't get me wrong. My caution on Canopy Growth stock doesn't mean that I'm advocating shorting CGC. I'm nowhere near ready to put Canopy Growth stock in the same boat as Tilray (NASDAQ:TLRY) whose fortunes have gone up in smoke over the past several months. However, considering the volatility of the cannabis market and the CGC stock chart, the shares aren't close to worth buying if history is any indicator. CGC Stock's Daily ChartThe volatile and some might say temperamental behavior of CGC stock has foiled bulls' attempts to exploit its positive trend using breakout strategies. That is illustrated by higher and above-average volume buy signals sent by triangle patterns, a classic short-handle consolidation and a very recent failed breakout as relative highs were cleared.But Canopy Growth stock has also been somewhat of an equal opportunity trap for bears too.The chart of CGC stock depicts a couple of breakdowns of CGC that were reversed. There was last summer's out-of-left-field explosive gain on partnership news with beverage giant Constellation Brands (NYSE:STZ). And earlier this spring a bear flag similarly failed after breaking down courtesy of a rally a short while later.Of course, some bulls might be quick to point out that, during both bearish patterns, CGC did not fall below the support provided by its 200-day simple moving average. That incidentally made CGC stock ripe for buying. That's true, but there's always a technical line on the price chart somewhere that drive buy decisions which work out favorably. The Bottom Line on CGCIn our view, CGC stock's squiggly price line is a tricky one to trade. And given the shares' history of volatile failures in the wake of breakdowns and breakouts, today's pullback pattern isn't a reason to sell Canopy Growth, but it does not make CGC worth buying just yet.Disclosure: Investment accounts under Christopher Tyler's management do not currently own positions in any securities mentioned in this article. The information offered is based upon Christopher Tyler's observations and strictly intended for educational purposes only; the use of which is the responsibility of the individual. For additional options-based strategies and related musings, follow Chris on Twitter @Options_CAT and StockTwits. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Buy that Lost 10% Last Week * Top 7 Dow Jones Stocks of 2019 -- So Far * 5 Service Stocks That Can Win the Trade War -- According to Goldman Sachs Compare Brokers The post Why Canopy Growth Stock Isna€™t Worth Buying Yet appeared first on InvestorPlace.

  • Freshford Capital Management’s Return, AUM, and Holdings
    Insider Monkey3 days ago

    Freshford Capital Management’s Return, AUM, and Holdings

    Freshford Capital Management was launched back in 2008 by Michael G. Doheny. The firm has its headquarters in Rye Brook, New York and primarily focuses in long/short investments in the public equity markets in the United States. Michael Gerard Doheny is the principal owner and President at Freshford Capital Management. He holds a B.S. in […]

  • MoneyShow3 days ago

    Three Conservative Ways to Play Cannabis

    Forget the marijuana stocks, as their partners are more of a sure thing, asserts Mark Leibovit, growth stock expert and editor of The VR Cannabis Letter.

  • 3 Reasons Not to Sell Canopy Growth Stock
    InvestorPlace4 days ago

    3 Reasons Not to Sell Canopy Growth Stock

    After years of hype, pot stocks finally went parabolic in mid-2018 after big money started to enter the space. Some called the parabolic move higher in pot stocks a bubble. Others called it an opportunity. The latter group was right. Turns out, pot stocks aren't Bitcoin 2.0. Instead, pot stocks have great long term growth fundamentals, rooted mostly in the fact that current trends imply that recreational cannabis will one day be as big as (if not bigger than) the $500 billion-plus global alcoholic beverage and tobacco markets.Source: Shutterstock At the head of the group is Canopy Growth (NYSE:CGC). Canopy is the unparalleled leader in the fully legal Canadian cannabis market. They also have one of the largest production footprints in the cannabis industry, a $4 billion investment from Constellation Brands (NYSE:STZ) on the balance sheet, and a deal in place to acquire big U.S. cannabis company Acreage once cannabis becomes fully legal in the U.S.In other words, Canopy Growth is the runaway leader in the global cannabis market, and projects to be the leader of this potential $500 billion-plus industry in the future. That's why CGC stock is up 60% year-to-date, and 90% over the past year.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Retirement Stocks That Won't Wilt in a Bear Market But CGC stock has run into some turbulence recently. Over the past three weeks, CGC stock has dropped nearly 20% off its late April all time highs.Investors shouldn't be concerned about this weakness. Instead, they should embrace it. This weakness is nothing more than an opportunity to accumulate a long-term winning stock at a winning price. Why? There's three big reasons why investors shouldn't sell Canopy Growth stock here. Those reasons are as follows. Trade-Related Headwinds Could Reverse CourseThe first big reason not to sell CGC stock here is that the headwinds which have sparked the sell-off aren't all that relevant -- and they could reverse course pretty soon.CGC stock didn't fall in isolation. It dropped alongside a market meltdown which was sparked by escalating trade war tensions and a fresh round of tariffs. But none of this is all that relevant to Canopy Growth, which is a Canada-based cannabis company that gets most of its revenue from Canada and doesn't have much U.S-China trade risk or exposure. Thus, macro headwinds are creating unnecessary weakness in Canopy stock.Further, these headwinds could reverse course soon. U.S. President Donald Trump has married himself to the stock market, and this fresh round of tariffs has a grace period for in-transit goods. That combination ultimately implies that the U.S. wants to get a deal done soon. China does, too, since the entire 2019 rebound in their economy has been predicated on improving trade conditions. As such, it's fairly likely these two nations reach a trade agreement fairly soon, in which case current macro headwinds will soon turn into macro tailwinds, and the current sell-off in CGC stock will turn into a rally. The Canadian Market Will Be Just FineThe second reason not to sell CGC stock is that concerns related to a Canadian cannabis market slowdown are overstated.There have been some concerns that the Canadian cannabis market is slowing. Those concerns stem from Canadian cannabis company Cronos (NASDAQ:CRON) reporting weaker-than-expected first-quarter numbers, as well as new survey from Dalhousie University which implies that enthusiasm for legal edibles isn't all that high. There are also some new licensing rules at play in the Canada market which could exacerbate the ongoing supply shortage problem, which has led to unimpressive cannabis sales ramp in early 2019.But, these are all near-term concerns. In the big picture, young consumers globally like to smoke weed more than they like to drink alcohol, and that will ultimately manifest itself into big demand globally. Sure, demand may be fickle today, but that's probably because the industry is so new, consumers don't know how to buy cannabis legally at scale, and there are supply shortages everywhere. All these things will get fixed over time. As they do, near-term headaches will turn into long-term gains, and that will ultimately power CGC stock way higher. The Big U.S. Market Tailwind Has Yet to ArriveThe third reason not to sell CGC stock is that the stock's biggest catalyst hasn't even arrived yet.In the cannabis world, the Canadian cannabis market is small peanuts. Most analysts peg it as somewhere around a $10 billion potential market. The golden goose here is the U.S. cannabis market, which is pegged at a $100 billion potential market, or roughly tenfold that of the Canadian market. Thus, all these near-term concerns surrounding supply shortages in the nascent Canadian cannabis market are really small in the big picture.In that big picture, it's all about the U.S. market, which Canopy is set to dominate thanks to its deal to acquire Acreage upon legalization of cannabis in the U.S. That huge catalyst hasn't even arrived yet. Selling a stock before its big catalyst has even arrived is short-sighted. * 7 Forever Stocks to Buy for Long-Term Gains Bottom Line on CGC StockCGC stock has been a big winner over the past year and in 2019 for a reason: this is a global cannabis company that is in the first inning of a huge, long-term growth narrative that could one day produce a $100 billion company.Canopy stock has dropped over the past few weeks. But nothing about that long term growth narrative has changed. Consequently, investors should embrace recent weakness as an opportunity add on the dip.As of this writing, Luke Lango was long CGC. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Retirement Stocks That Won't Wilt in a Bear Market * 5 Consumer Stocks Ready to Push Higher * 3 of the Best ETFs to Buy for a Play on Gold Stocks Compare Brokers The post 3 Reasons Not to Sell Canopy Growth Stock appeared first on InvestorPlace.

  • CNBC4 days ago

    Your first trade for Wednesday, May 15

    The "Fast Money" traders share their first moves for the market open.

  • What's on the Way From Canopy Growth Based on Its Latest U.S. Trademark Applications
    Motley Fool4 days ago

    What's on the Way From Canopy Growth Based on Its Latest U.S. Trademark Applications

    The Canadian cannabis producer appears to be set to make its mark in the potentially lucrative U.S. hemp market.

  • GlobeNewswire4 days ago

    Modelo Joins Forces with Leave No Veteran Behind through The Modelo Fighting Chance Project

    Modelo, the beer brewed for those with The Fighting Spirit™, is expanding its cause marketing campaign – The Modelo Fighting Chance Project – with a new partner: Chicago-based nonprofit Leave No Veteran Behind. Modelo’s funding will provide educational scholarships and support Leave No Veteran Behind’s transitional jobs program, offering veterans a fresh financial start so they can continue to serve their communities.

  • Here's Where Craft Brew Alliance's Kona+ Strategy Really Starts Paying Off
    Motley Fool4 days ago

    Here's Where Craft Brew Alliance's Kona+ Strategy Really Starts Paying Off

    The brewer continues to benefit from Kona's Hawaiian roots as regional beer popularity remains high.

  • If Aurora Stock Falls on Earnings, Buy the Dip
    InvestorPlace5 days ago

    If Aurora Stock Falls on Earnings, Buy the Dip

    Canadian cannabis giant Aurora (NYSE:ACB) is set to report third-quarter earnings after the bell on Tuesday. Investors shouldn't get too excited about the report. Long story short, pot sales appear to have stagnated in Canada in the early part of 2019, mostly due to demand confusion and supply shortages, and affecting marijuana stocks. Thus, Aurora's numbers likely won't be all that great, and ACB stock could drop in response.Source: Shutterstock But the third-quarter earnings report and subsequent stock price reaction are just noise for Aurora. Zooming out, the long-term growth fundamentals supporting ACB stock are healthy, and the valuation underlying the stock is very attractive relative to its marijuana stock peers. Further, it does seem like only a matter of time before Aurora scores a big-time consumer staples investment. Once it does, this stock's relative valuation discount to peers will cease to exist, and Aurora stock will soar.In other words, when it comes to ACB stock, it's all about the big picture, and a quarterly earnings report just a few months into Canadian cannabis market legalization isn't a big deal in that big picture. All Aurora needs to do this quarter is report triple-digit sales and volume growth -- preferably with both above 300% -- and the company will have affirmed that it is the number two player in this market, only narrowly behind Canopy Growth (NYSE:CGC) in terms of sales and volume.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut Canopy is a $15 billion company. Aurora is an $8.5 billion company. Thus, if Aurora does affirm that it is right behind Canopy this quarter, then the long term bull thesis supporting ACB stock will remain in-tact. The Quarter Will Be Mixed for ACB StockAurora's third quarter numbers likely won't be that great. But, they won't be awful either. Instead, they will likely be a mixed bag with big but slowing growth rates. * 6 Trade War Stocks With a Lot of Risk Context is important here. It increasingly appears that the Canadian cannabis market got off to a sluggish start in the new year. Aurora's peer, the high-flying Cronos (NASDAQ:CRON), recently reported weaker than expected first quarter sales and volume numbers. Revenues rose just 15% quarter-over-quarter, while volumes rose just 7% sequentially. These relatively muted quarter-over-quarter growth rates corroborate government numbers, which show an unimpressive cannabis sales ramp in early 2019 wherein cannabis sales in early 2019 are essentially flat with sales in late 2018.Against that backdrop, it looks likely that Aurora will similarly report weaker than expected third quarter sales and volume numbers which comprise muted sequential growth. Investors won't like that. This early in the game, growth should be ramping sequentially. If it's not, investors will be disappointed, and selling will ensue.To be sure, the numbers will still look great on a year-over-year basis. I fully expect revenues and volumes to still rise 300%-plus year-over-year, which is very impressive. As such, growth will remain big. Just not big enough.Net net, Aurora's third-quarter numbers will likely be a mixed bag that comprises big but slowing growth. Investors won't be too impressed with the slowing growth part, and ACB stock could fall in response. Aurora Stock Looks Good for the Long TermIn the big picture, mixed third-quarter 2019 numbers from Aurora aren't all that important. Instead, what is important is that Aurora is the second-biggest player in the Canadian cannabis market, with a stock that's trading at a dirt cheap valuation relative to peers. This valuation discount won't last forever. When it closes, ACB stock will fly higher.First, it is important to understand that the cannabis market will be huge. Young consumers like to smoke weed more than they like to drink, and this will ultimately manifest itself into huge demand for cannabis around the world. Eventually, all this demand will filter through the legal channel once consumer confusion clears up and supply shortages are fixed. Broadly, then, the legal recreational cannabis market could one day be as large as the alcoholic beverage and tobacco markets. Those are $500-billion-plus markets.Right now, the testing grounds for this global $500-billion-plus potential market is in Canada, since that's where cannabis is fully legal today. In that testing ground, Aurora is the second-largest player, with a revenue and volume base that dwarfs Cronos and Tilray (NASDAQ:TLRY), and is only slightly behind Canopy. Yet, despite being the second-largest player in Canada, Aurora has a market cap that is only slightly larger than Cronos and Tilray, and well smaller than Canopy. Indeed, the market is valuing each kilogram of cannabis sold by Aurora last quarter at just $1.2 million, versus $1.5 million at Canopy, $2.3 million at Tilray, and $4.6 million at Cronos.Why the relative valuation discrepancy? The company doesn't have a major investment from a consumer staples giant. Canopy has a roughly $4 billion investment from Constellation Brands (NYSE:STZ). Cronos has a roughly $2 billion investment from Altria (NYSE:MO). But this is only a temporary problem. As the second-largest cannabis company in Canada trading at a huge discount to peers and growing just as quickly, Aurora is in a great position to receive big-money interest soon.Once the company does get a big-money offer, then Aurora stock will fly higher. Bottom Line on ACB StockAurora's third-quarter numbers likely won't be great, and ACB stock could fall in response.But, zooming out, the big-picture fundamentals supporting Aurora remain intact. Namely, the cannabis market still projects to be huge one day, Aurora is currently the number two player in that market, and a big money investment will likely arrive sometime later this year. So long as those three things remain true, then the relative valuation discount in ACB shouldn't exist, and buyers here should be rewarded in the long run.As of this writing, Luke Lango was long ACB and CGC. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 6 Trade War Stocks With a Lot of Risk * 7 Bond ETFs to Buy * 10 Stocks That Could Squeeze Short Sellers, Including CGC Compare Brokers The post If Aurora Stock Falls on Earnings, Buy the Dip appeared first on InvestorPlace.

  • The Top 5 Beer Stocks of 2018
    Investopedia5 days ago

    The Top 5 Beer Stocks of 2018

    The top beer stocks have a market cap exceeding $2 billion and are trading on leading American stock exchanges. Here are the top beer stocks of 2018.

  • Constellation Brands (STZ) Stock Moves -1.01%: What You Should Know
    Zacks5 days ago

    Constellation Brands (STZ) Stock Moves -1.01%: What You Should Know

    Constellation Brands (STZ) closed at $201.17 in the latest trading session, marking a -1.01% move from the prior day.

  • Charts Indicate That the Risk/Reward Ratio of Cronos Stock Is Reasonable
    InvestorPlace6 days ago

    Charts Indicate That the Risk/Reward Ratio of Cronos Stock Is Reasonable

    Cronos (NASDAQ:CRON) stock dropped almost 10% on Thursday after the company's fiscal first-quarter results were released. For those who regularly trade CRON stock, the decline was not surprising. Nor was the bounce of CRON stock on Friday. CRON stock remains locked in a downtrend.Is now the time for long-term bulls to buy Cronos stock? Down over 50% from its highs, one would think the stock could rise above its current levels, while others may think it's the start of an even larger correction. On the plus side, the risk/reward scenario of Cronos Group stock could become favorable soon.Before we look at the charts though, remember that Cronos stock is a speculative investment. Personally, I prefer buying names like Canopy Growth (NYSE:CGC) and Aurora Cannabis (NYSE:ACB) on deep pullbacks. That said, some think that CRON stock has potential, so let's take a look.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Dividend Stocks to Buy as the Trade War Reignites Trading CRON StockIt's clear that $24-$25 is resistance on the chart, while CRON stock is locked in a violent downtrend. Even a rally up to $16 might just result in additional selling pressure. The 21-day moving average is around the same area as its downtrend resistance, so I would expect CRON stock to fail to hold that level.That said, the technical outlook of Cronos stock looks promising at its current levels. Throughout the third and fourth quarters of 2018, $13 -$14 was resistance for CRON stock. After breaking through this level in January, many investors will expect it to act as support.It helps that the downtrend support of Cronos Group stock is coming into the picture around current levels and that the 200-day moving average sits at $13.28. If CRON falls below the 200-day, the shares could reach $12 and single-digits after that.But let's not get ahead of our skis here. See if CRON stock can stay above its nearby support. A bounce could send it higher by more than 14% to its current resistance. If it breaks below the support level, investors should wait for a more favorable price. The Bottom Line on Cronos Group Stock(Note: the below figures are in Canadian dollars)In Q1, CRON churned out a GAAP profit of 42 cents on revenue that grew 120% year-over-year (YoY). Here's the thing though: it reported just $6.5 million of revenue. That's right; this company, with a $4.5 billion market cap, registered sales of just $6.5 million in Q1.Its top line more than doubled from the same period a year ago, but at what point is its valuation a bit ridiculous? Analysts do expect its rapid growth to continue for the rest of this year. In Q2, they, on average,are calling for $6.76 million of sales, up 160% YoY. In Q3 and Q4, the consensus estimates ramp dramatically to $13 million and $22.9 million, up 360% and 334% YoY, respectively.But based on those estimates, CRON stock is valued at roughly 90 times its 2019 sales. That's a tough pill to swallow.That said, there's demand for this stock and many others like it. Constellation Brands (NYSE:STZ) has taken a massive stake in CGC, while Aurora Cannabis has talked about a collaboration with Coca-Cola (NYSE:KO). Cronos Group stock received a $1.8 billion investment from Altria (NYSE:MO) in exchange for a 45% stake.The point is that many investors -- from retail to conglomerates in the tobacco and alcohol industry -- view the cannabis industry as a rising, long-term play. Getting in now is costly, but those who are patient are essentially guaranteed a seat at the table. The question is how valuable that seat will be worth and how long it will take to realize its potential. It's clear there is a non-cyclical trend toward cannabis and cannabis-related products and for that reason, a speculative position may make sense for some investors. But don't forget, it is speculative.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dividend Stocks to Buy as the Trade War Reignites * 10 Stocks That Could Squeeze Short Sellers, Including CGC * 5 Tech Stocks Getting Crushed Compare Brokers The post Charts Indicate That the Risk/Reward Ratio of Cronos Stock Is Reasonable appeared first on InvestorPlace.

  • Do You Know What Constellation Brands, Inc.'s (NYSE:STZ) P/E Ratio Means?
    Simply Wall St.6 days ago

    Do You Know What Constellation Brands, Inc.'s (NYSE:STZ) P/E Ratio Means?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Better Buy: Canopy Growth vs. Aphria
    Motley Fool7 days ago

    Better Buy: Canopy Growth vs. Aphria

    Two leading marijuana stocks. One clear winner.

  • 'Jeopardizing my children's lifestyle': Marijuana industry moms face a unique stigma
    Yahoo Finance7 days ago

    'Jeopardizing my children's lifestyle': Marijuana industry moms face a unique stigma

    Women in the cannabis industry use various tactics to counter the stigma of working in the nascent field.

  • 5 Stock Picks That Now Pay Dividends
    Kiplinger9 days ago

    5 Stock Picks That Now Pay Dividends

    Retirees take note: Dividend stocks have been proven to outperform their non-paying peers over time.

  • Sam Adams: Gone Dogfishin’
    Bloomberg9 days ago

    Sam Adams: Gone Dogfishin’

    Koch is the founder, chairman and pint-holding face of Boston Beer Co., better known as the maker of Samuel Adams Boston Lager. This week, the company announced a $300 million deal for Dogfish Head Brewery, its largest acquisition in the more than three decades that Boston Beer has been in business. It’s partly an opportunistic move by Koch, as valuations for craft brewers have come down in recent quarters.

  • Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?
    Zacks9 days ago

    Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?

    Style Box ETF report for DEF

  • Canopy Growth’s M&A Strategy Is a Good Bet
    InvestorPlace10 days ago

    Canopy Growth’s M&A Strategy Is a Good Bet

    After a strong January performance, Canopy Growth (NYSE:CGC) has struggled to break materially higher over the past few months. This is in spite of a slew of announcements of new partnerships, new ventures and geographic expansion.Source: Shutterstock It may well be that investors are waiting to see the CGC closer to profitability or are waiting on further favorable regulatory changes. In the meantime, it's clear that Canopy Growth is putting that $4 billion investment from Constellation Brands (NYSE:STZ) to use.That said, CGC stock has remained range bound -- call it between $40 and $50 -- since late January. After a strong first quarter and M&A activity on the rise, there is reason to believe CGC stock could break out in the second half of the year. April has been a busy M&A month, and progress in these tuck-in investments is one of many catalysts that could drive the stock higher.InvestorPlace - Stock Market News, Stock Advice & Trading Tips CGC Stock Bets on Therapeutic Spectrum Therapeutics is CGC's newly unveiled global brand that will consolidate all of the company's ongoing commercial medical and clinical research operations. It will include the acquisition of C3 Cannabinoid Compound Company, which is Europe's largest cannabinoid-based pharmaceuticals company.The C3 acquisition will fuel CGC's leadership in medical cannabis on a global scale. They get a stronger toehold via a strong R&D operation and distribution network in Europe. This integration is setting the stage for what could be a proper cannabis healthcare company in its own right. The scope of their services extends beyond research and treatment to education and overall wellness, a winning combination. * 10 Great Stocks to Buy on Dips Spectrum Therapeutics is already providing commercially available medical cannabis products on five continents, but there is still plenty of room to fill-in those markets. CGC Takes Another Big Step Toward Entering the U.S. Market Last month, CGC also acquired Acreage. Acreage is a leading multi-state operator in U.S. cannabis. It owns or has managed services agreements in place for cannabis-related licenses across 20 states (giving it the right to develop), including 87 dispensaries and 22 cultivation and processing sites.The combined operations of the two companies would create the undisputed leader in U.S. cannabis. Recall that the U.S. is a market where CGC does not yet have a major presence.As Bruce Linton, Chairman and co-CEO, commented,"Our [CGC] right to acquire Acreage secures our [CGC] entrance strategy into the United States as soon as a federally-permissible pathway exists … By combining Acreage's management team, licenses and assets with Canopy Growth's intellectual property and brands, there will be tremendous value creation for both companies' shareholders."It doesn't stop there. In mid-April, CGC also announced an all-cash acquisition of Spain-based licensed cannabis producer Cañamo y Fibras Naturales, S.L. (Cafina).While the regulatory situation in the U.S. remains uncertain still, CGC has charged ahead in other markets. The Cafina acquisition gives Canopy Growth access to an ideal growing region. Cafina is one of three companies in Spain authorized to cultivate, distribute and export cannabis containing more than 0.2% of THC for medicinal and research purposes.This is a promising foundation for expansion in Spain and Europe broadly. It's a smart move to diversify within the E.U. CGC already has a facility in Denmark and adding yet another in a different country will help CGC increase revenue in the E.U. free of supply constraints.Mark my words, this will not be the last acquisition that CGC announces. The market may not be giving credit right now for this strategy, but as the numbers roll in, a re-rating on CGC stock will be in order.As of this writing, Luce Emerson did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dangerous Dividend Stocks to Stay Far Away From * 7 Tips for New Investors Young and Old * 10 Great Stocks to Buy on Dips Compare Brokers The post Canopy Growth's M&A Strategy Is a Good Bet appeared first on InvestorPlace.

  • The Payoff on Constellation Brands' Big Bet on Beer Isn't Over Yet
    Motley Fool10 days ago

    The Payoff on Constellation Brands' Big Bet on Beer Isn't Over Yet

    Despite the beer industry's decline, its Mexican brands still have a lot of growth ahead.

  • Beer industry is 'maturing,' according to a local craft brewery partner
    Yahoo Finance Video9 days ago

    Beer industry is 'maturing,' according to a local craft brewery partner

    Bruce Wilpon, the Managing Partner of Mikkeller NYC brewery, talks to Yahoo Finance's Brian Sozzi and Alexis Christoforous about the overall state of the beer industry and his local brewery at New York Mets Citi Field. Wilpon also weighs in on hi hope to partner up with Uber Eats.

  • PLUS revenue up 684% YOY, how it remains competitive in the cannabis space
    Yahoo Finance Video11 days ago

    PLUS revenue up 684% YOY, how it remains competitive in the cannabis space

    The California-based company PLUS is a small business that's looking to disrupt the cannabis industry. Yahoo Finance talks to Jake Heimark, the CEO of PLUS products, about its strong revenue growth year over year, new products set to launch this year and how it's shaping up in the crowded space.